evista
08 »
evista
RaloxifeneSystematic (IUPAC) name- phenyl] -methanoneIdentifiersCAS number84449-90-1ATC codeG03XC01PubChem5035DrugBankAPRD00400Chemical dataFormulaC28H27NO4S Mol. mass473.584 g/molSMILESeMolecules & PubChemPharmacokinetic dataBioavailability2%Protein binding95%MetabolismHepatic glucuronidationCYP system not involvedHalf life27.7 hoursExcretionFecalTherapeutic considerationsLicence dataEU EMEA:link, US FDA:linkPregnancy cat.X(AU) X(US)Legal status℞ Prescription onlyRoutesOralRaloxifene is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women. It was announced on April 17, 2006, that raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in certain high risk groups of females, though with a reduced risk of thromboembolic events and cataracts in patients taking raloxifene versus those taking tamoxifen. On September 14, 2007, the U.S. Food and Drug Administration announced approval of raloxifene for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.There has been criticism in the mainstream oncology press of the way that information about the drug was released. There has been some confusion in the lay media about the meaning of the trial results. There is no specific clinical evidence for the use of raloxifene in the adjuvant treatment of breast cancer over established drugs such as tamoxifen or anastrozole.Raloxifene is produced by Eli Lilly and Company and is sold under the brand name Evista.// DescriptionRaloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S•HCl, which corresponds to a molecular weight of 510.05 g/mol. Raloxifene HCl is an off-white to pale-yellow solid that is slightly soluble in water.SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as Pfizer's lasofoxifene and Wyeth's bazedoxifene are in the later development phases. IndicationRaloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate. Contraindications and precautionsRaloxifene is contraindicated in lactating women or women who are or may become pregnant, in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis and in women known to be hypersensitive to raloxifene. Adverse reactionsCommon adverse events considered to be drug-related were hot flashes and leg cramps.Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes.Raloxifene is a teratogenic drug.In a 2006 study published in New England Journal of Medicine, raloxifene produced significantly more strokes and blood clots than the placebo. As cancer drugRaloxifene reduces the risk of hormone-positive breast cancer and vertebral fractures "without a shadow of a doubt," but its effects on cardiovascular disease remain less certain, according to the results of the "Raloxifene for Use of the Heart" (RUTH) study published in the July 13, 2006 issue of the New England Journal of Medicine by Dr. Elizabeth Barrett-Connor (University of California at San Diego) and colleagues.In the trial, in women with coronary heart disease (CHD) or multiple risk factors for CHD, raloxifene had no significant effect on the primary end point, coronary events, but it did significantly increase the risk of venous thromboembolism (VTE). And although the drug had no effect on stroke, there was a seemingly paradoxical significant increase in death from stroke.On September 14, 2007, Steven K. Galson, then director of the United States Food and Drug Administration's Center for Drug Evaluation and Research announced authorization of the sale of raloxifene to prevent invasive breast cancer in post-menopausal women.
Buy Evista 60 mg, cheap generic Evista 60 mg online from offshorerx, Osteoporosis drug". Evista, a drug for post-menopausal women for the treatment of osteoporosis has now been found to greatly decrease the risk of breast cancer.Shasta Pools in Phoenix is leveraging MFP devices, eCopy Scanstations, and the Optiscan eVista Document Management System to save 500,000 a year in paper costs. Such a feat has now been duplicated with Parksinsonâs disease with the drug Isradapine. Evista should not be prescribed for all women because of serious side effects.Evista has fewer side effects and could reduce the risk of developing invasive breast cancer by 50 per cent. Company Eli Lilly and Company.This category includes products for breast enlargement (Breast Success), fertility stimulation (Clomid), treating fungal infections caused by Candida albicans and Cryptococcus neoformans (Diflucan), hormone therapy (Evista), men attraction (Euphoria perfume), treatment of severe vasomotor symptoms of the menopause (Premarin) and increasing a woman'Breast enhancement gallery, breast enhancement new london ct, buy viagra zenegra, breast enhancement a to c, buy evista free shipping, brite now dental seattleEuflexxa Lipitor Actonel Fosamax Effexor Protonix Plavix Celebrex Flomax Nexium Synvisc Prevacid Evista Juvederm Orthovisc Restylane Zyprexa HyalganEuflexxa Lipitor Actonel Fosamax Effexor Protonix Plavix Celebrex Flomax Nexium Synvisc
Even more about evista
evista
On our site you have search description of pills ... Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor ...
Evista
Eli Lilly намерена получить разрешение на применение препарата Evista для профилактики рака груди
Финансовые новости архив: Eli Lilly ...
Learn about Evista from the publishers of the Physicians Desk Reference. Find prescription drug information resources including interactions, side effects, symptoms, treatment, and ...
Evista | Prescription Drug Information, Side Effects | PDRHealth
Information about osteoporosis and invasive breast cancer and how to reduce the risks for both with EVISTA® (raloxifene HCl), a prescription medication for postmenopausal women ...
EVISTA® (raloxifene HCl): Osteoporosis and Invasive Breast Cancer
EVISTA® (raloxifene HCI) benefits postmenopausal women by preventing bones from getting weaker and treating osteoporosis.
Comment:
